Bloomberg Law News: Bluebird Is Sued Over Patents Related to Blood-Disease Drug

Bluebird Bio’s LentiGlobin and Zynteglo infringe two patents for recombinant vectors used in the treatment of rare blood disorders, closely held Errant Gene Therapeutics claims in a new lawsuit.

View the rest of the article here

View the PDF